Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CMC Biologics, a biopharmaceutical contract manufacturing organization, has been issued European Patent covering a method for improving productivity in microbial fermentations and mammalian cell culture bioreactors.
Subscribe to our email newsletter
The process helps optimize production of a biotherapeutic in a continuous perfusion fermentation process, wherein the bioreactor (fermenter) has an ultrafiltration system that allows impurities to be removed while retaining cells in the bioreactor.
Perfusion bioreactors involve continuous cell culture, feeding, and withdrawal (harvesting) of product and accumulates no waste products, thereby creating a stable cell growth environment.
CMC Biologics chief scientific officer Mads Laustsen said CMC Biologics is witnessing progress of biopharmaceutical manufacturing to the next level.
"This proprietary technology demonstrates that using the impurity filter improved cell density, productivity and product concentration – all critical to helping our customers move their products to market on time and on target," Laustsen added.